Logo
Menu
  • Who We Are
  • How We Invest
  • Our Portfolio
    • Abzena
    • Ixlayer
    • Kiniciti
    • PathAI
  • Blog
  • Careers
  • Contact
Interview with Zach Weinberg

Interview with Zach Weinberg

by Biospring | May 30, 2022 | Curie Bio, EHR, Flatiron Health, Pharma, RWD, RWE, Zach Weinberg

Zach Weinberg is a Co-Founder of Curie Bio and Operator Partners. Zach was previously Co-Founder, President, and COO of both Flatiron Health (acquired by Roche in 2018 for $2B) and Invite Media (acquired by Google in 2010 for $81M). Zach is one of the most successful...
The Opportunities for AI in Drug Discovery

The Opportunities for AI in Drug Discovery

by Biospring | Apr 26, 2022 | Artificial Intelligence, Data, Drug Discovery, Health Care, John Baldoni, Pharma

We recently hosted a discussion with Dr. John Baldoni, one of Biospring’s Operational Experts. He is the Co-Founder and Chief Scientific Officer of SaponiQx, a recently formed vaccine discovery and development company. He’s also the CEO of the Atom...
Cell and Gene Therapy 101: A Primer on Advanced Therapies

Cell and Gene Therapy 101: A Primer on Advanced Therapies

by Biospring | Apr 26, 2022 | Biotech, Cell and Gene Therapy, Cell Therapy, CGT, Gene Therapy, Pharma

What if instead of treating the symptoms of a disease, we could target the source of the disease itself? Cell and Gene Therapy (C&GT) can do just that. These advanced therapies are the result of decades of research on the building blocks (cells) and blueprints...
Synbio 101: A primer on the next big life sciences technology

Synbio 101: A primer on the next big life sciences technology

by Biospring | Apr 25, 2022 | DNA, Drug Development, Drug Discovery, Manufacturing, Pharma, Supply Chain, Sybio, Synthetic Biology

Synthetic biology (synbio) is a life sciences technology that is transforming a broad range of industries including agriculture, chemicals, food, and medicine. Synbio applies engineering principles to biology and uses genomics to “code” organisms to yield a desired...
Abzena update with Sven Lee

Abzena update with Sven Lee

by Biospring | Apr 25, 2022 | Abzena, Biologics, Biotech, CDMO, COVID-19, Drug Development, Drug Discovery, Drug Manufacturing, Pharma, Sven Lee

We shared an overview on Abzena following our investment in July. Over the past few months, Abzena has launched a new facility in San Diego and has made several executive hires. We recently spoke with Sven Lee, Chief Business Officer at Abzena, and he provided us with...
Professor Graham Richards on Computer-Aided Molecular Design

Professor Graham Richards on Computer-Aided Molecular Design

by Biospring | Apr 24, 2022 | Chemistry, Computer Aided Molecular Design, Drug Design, Graham Richards, Oxford, Pharma

Professor Graham Richards is Commander of the Order of the British Empire and former Head of Chemistry at the University of Oxford. He is a pioneer in the field of computational chemistry and computer-aided molecular design, particularly as it applies to the...
« Older Entries

Recent Posts

  • Biospring Partners Welcomes Industry Executives To Its Advisory Board
  • Biomanufacturing: A Growing Field
  • Interview with Zach Weinberg
  • Driving Drug Development with Data Science
  • Proteomics 101

Recent Comments

No comments to show.

Newsletter

Thank you for subscribing!

Subscribe